Skip to main content
Clinical Trials/CTRI/2021/04/032726
CTRI/2021/04/032726
Completed
未知

A Prospective Observational Multicentric Clinical Trial to evaluate microscopic examination of various clinical samples by Artificial Intelligence based system - AI Microscopy

Sevamob Ventures Limited0 sites1,200 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: D649- Anemia, unspecifiedHealth Condition 2: B359- Dermatophytosis, unspecifiedHealth Condition 3: A159- Respiratory tuberculosis unspecifiedHealth Condition 4: N390- Urinary tract infection, site notspecified
Sponsor
Sevamob Ventures Limited
Enrollment
1200
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
January 31, 2022
Last Updated
3 years ago
Study Type
Observational

Investigators

Sponsor
Sevamob Ventures Limited

Eligibility Criteria

Inclusion Criteria

  • 1\.Inclusion criteria for superficial fungal infections: The patients visiting the skin outpatient department (OPD) in the hospital settings and suspected of fungal infections in skin or hair or nail by the dermatologist.
  • 2\.Inclusion Criteria for community acquired lower Urinary Tract Infection (UTI): All the patients of symptomatic UTI ââ?°Â¥18 years old from community with complaints of burning micturition and urgency.
  • And not been admitted into the hospital for more than 48 hours in previous 1 month.
  • 3\.Inclusion criteria for Blood smear examination: We will include 400 patients who are coming for routine Complete blood count (CBC) evaluation in haematology unit of Department of Pathology. Consent will be taken from the patient/ patient attendant when they will come for routine CBC in hematology lab.
  • 4\.Inclusion criteria for pulmonary tuberculosis: Cases of suspected pulmonary tuberculosis whose sputum samples are submitted for AFB microscopy.

Exclusion Criteria

  • 1\.Exclusion criteria for superficial fungal infections: Patients on antifungal therapy (oral as well as topical) for last 2ââ?¬â??3 months. Patients with documented bacterial skin infections.
  • 2\.Exclusion Criteria: Patients who had been on antibiotics 2 weeks or earlier prior to the study. Patients on phenazopyridine use in the prior 2 day, or with symptoms or signs of pyelonephritis, recent catheterization, or known anatomic or functional abnormalities of the urinary tract.
  • 3\. All the patients of Aplastic anaemia, patients on chemotherapy and radiotherapy.
  • 4\. Extra pulmonary tuberculosis, children/patients unable to expectorate sputum, patients unwilling to give consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials